| ORIGINAL HYPOTHESIS |
|
| Year : 2015 | Volume
: 6
| Issue : 2 | Page : 49-52 |
|
|
Possible neuroimmunomodulation therapy in T-cell-mediated oral diseases
Tsuyoshi Sato1, Michihiko Usui2, Yuichiro Enoki1, Shoichiro Kokabu3, Tetsuya Yoda1
1 Department of Oral and Maxillofacial Surgery, Saitama Medical University, Saitama, Japan
2 Division of Periodontology, Department of Oral Function, Kyushu Dental University, Fukuoka, Japan
3 Division of Molecular Signaling and Biochemistry, Department of Health Promotion, Kyushu Dental University, Fukuoka, Japan
Correspondence Address:
Dr. Tsuyoshi Sato
Department of Oral and Maxillofacial Surgery, Saitama Medical University, 38 Moro-hongou, Moroyama-machi, Iruma-gun, Saitama - 350-0495
Japan
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2155-8213.158472
|
|
|
Introduction: Recurrent aphthous stomatitis and oral lichen planus are local chronic inflammatory diseases which are implicated in T cell-mediated immunity. According to the systematic review, there is insufficient evidence to support any specific treatment for T-cell mediated oral diseases. The hypothesis: In this paper, we propose a hypothesis that recurrent aphthous stomatitis and oral lichen planus can be treated with selective α7 subunit of nicotinic acetylcholine receptor (α7 -nAChR) agonists. Our hypothesis is supported by the following two facts. First, the pathophysiological conditions, T h 1/T h 17 cell activation and autonomic nervous system dysfunction, are observed in T-cell mediated oral diseases as well as in T-cell mediated systemic diseases such as rheumatoid arthritis. Second, the cholinergic anti-inflammatory pathway is inhibited in systemic T-cell mediated chronic inflammatory diseases. On the other hand, treatment with α7 -nAChR agonists which activate the cholinergic anti-inflammatory pathway suppresses neuroinflammation via inhibition of T h 1/T h 17 responses in animal model of systemic T-cell mediated chronic inflammatory diseases. We thus expect that selective α7 -nAChR agonists will be effective for the treatment of T-cell mediated oral diseases. Evaluation of the hypothesis: To test our hypothesis, we need to develop in vivo mouse model of T-cell mediated oral diseases. To evaluate the therapeutic effect of a selective α7 -nAChR agonist, we choose ABT-107 because of its safety and tolerability. We believe that the selective α7 -nAChR agonist, especially ABT-107, may be a therapeutic drug to treat T-cell mediated oral diseases. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
